

AMENDMENTS TO THE CLAIMS

1. (currently amended) A cyotherapeutic unit comprising a plurality of potent cells; the content of said unit being known with respect to the identities and numbers of at least some of said plurality; the unit being assayed to ensure the accuracy of said identities and numbers; and the unit comprising cells from a plurality of sources, wherein one source of said plurality of sources is fetal cord blood, fetal tissue, a placenta, a postpartum placenta, or postpartum placenta perfusate.
2. (original) The cyotherapeutic unit of claim 1 wherein the accuracy of the assay is certified by the provider of the unit.
3. (original) The cyotherapeutic unit of claim 1 wherein the potent cells for which the identities and numbers are known are pluripotent cells.
4. (original) The cyotherapeutic unit of claim 1 wherein said identities reflect the presence or absence of at least one antigenic determinant on identified cells.
5. (currently amended) The cyotherapeutic unit of claim 1 wherein said unit comprises potent cells are obtained from fetal cord blood or other fetal tissue.
6. (currently amended) The cyotherapeutic unit of claim 1 wherein said unit comprises potent cells are obtained from fetal cord blood.
7. (currently amended) The cyotherapeutic unit of claim 1 wherein at least some of said potent cells are obtained from a placenta.
8. (currently amended) The cyotherapeutic unit of claim 1 wherein at least some of said potent cells are obtained from a postpartum placenta.
9. (currently amended) The cyotherapeutic unit of claim 1 wherein at least some of said potent cells are obtained from postpartum placenta perfusate.
10. (currently amended) The cyotherapeutic unit of claim 1 wherein (a) at least one

potent cell exhibits CD34, CD8, CD10, OCT4, CD38, CXCR4, or CD117 or (b) at least one potent cell is characterized as being CD10+, CD29+, CD34-, CD38-, CD44+, CD45-, CD54+, CD90+, SH2+, SH3+, SH4+, SSEA3-, SSEA4-, OCT-4+, or ABC-p+ or (c) at least one potent cell exhibits CD33 wherein potent cells for which the identities and numbers are known comprise at least some of cells exhibiting CD34, CD8, CD10, OCT4.

11. (cancelled)
12. (currently amended) The cyotherapeutic unit of claim 1 wherein potent cells are derived obtained from at least two individuals.
13. (currently amended) The cyotherapeutic unit of claim 1 wherein potent cells are derived obtained from at least 5 individuals.
14. (cancelled)
15. (original) The cyotherapeutic unit of claim 1 wherein at least one type of cell is excluded from the unit.
16. (original) The cyotherapeutic unit of claim 1 wherein the plurality of potent cells is selected to render the cyotherapeutic unit suitable for therapy for an indicated disease state or condition.
17. (original) The cyotherapeutic unit of claim 16 wherein at least one type of cell is excluded from the unit.
18. (currently amended) A cyotherapeutic unit comprising minimum numbers of at least two preselected types of potent cells, said unit comprising cells from a plurality of sources, wherein one source of said plurality of sources is fetal cord blood, fetal tissue, a placenta, a postpartum placenta, or postpartum placenta perfusate.
19. (original) The cyotherapeutic unit of claim 18 which has been assayed to ensure accuracy of its contents of preselected types of potent cells.

20. (currently amended) The cyotherapeutic unit of claim 18 wherein the contents of preselected potent cells isare certified.

21. (original) The cyotherapeutic unit of claim 18 wherein at least one type of cell is excluded from the unit.

22. (currently amended) The cyotherapeutic unit of claim 21 wherein the contents of preselected potent cells and the absence the types of cells to be excluded isare the subject of a certificationecertified.

23. (currently amended) The cyotherapeutic unit of claim 18, wherein said certification is of a plurality of potent cell types, said plurality and the numbers of each of said plurality being selected to render the cyotherapeutic unit suitable for therapy for an indicated disease state or condition.

24. (original) The cyotherapeutic unit of claim 23, wherein said certification is of a plurality of potent cell types, said plurality and the numbers of each of said plurality being selected as well as the types of cells excluded renders the cyotherapeutic unit suitable for therapy for an indicated disease state or condition.

25. (cancelled)

26. (currently amended) A kit for treatment of a person suspected of having a disease state or condition comprising a cyotherapeutic unit comprising a plurality of potent cells; the content of said unit being known with respect to the identities and numbers at least some of said plurality; the unit being assayed to ensure the accuracy of said identities and numbers; the unit comprising cells from a plurality of sources, wherein one source of said plurality of sources is fetal cord blood, fetal tissue, a placenta, a postpartum placenta, or postpartum placenta perfusate; and a certification of the accuracy of the assay.

27. (original) The kit of claim 26 wherein at least one type of cell has been excluded from the cyotherapeutic unit.

28. (currently amended) A kit for treatment of a person suspected of having a disease state or condition comprising (a) a cyotherapeutic unit comprising cells from a plurality of sources, wherein one source of said plurality of sources is fetal cord blood, fetal tissue, a placenta, a postpartum placenta, or postpartum placenta perfusate having minimum numbers of identified potent cells and (b) a certification of the potent cell composition of the unit.

29. (original) The kit of claim 28 wherein at least one type of cell has been excluded from the cyotherapeutic unit.

30. (cancelled)

31. (currently amended) A cyotherapeutic unit comprising (a) cells derived obtained from umbilical cord blood and (b) cells obtained from a placenta, or a mixture thereof, wherein at least one type of cell has been removed from the unit.

32. (original) The cyotherapeutic unit of claim 31 wherein a plurality of cell types have been removed from the unit.

33. (cancelled)

34. (currently amended) A cyotherapeutic unit comprising (a) cells derived obtained from umbilical cord blood, or (b) cells obtained from a placenta, or (c) a mixture of cells derived from umbilical cord blood and cells obtained from a placenta thereof, said cells comprising a plurality of different types, at least some of the different types having been separated into components and recombined into said unit.

35. (original) The cyotherapeutic unit of claim 34, wherein said separated cell types have been frozen separately.

36. (original) The cyotherapeutic unit of claim 34, in a frozen state.

37. (original) The cyotherapeutic unit of claim 34, wherein said separated cell types

have been characterized.

38-49. (cancelled)

50. (currently amended) A library of cyotherapeutic units, each unit member of said library comprising a plurality of potent cells; each of said units comprising cells from a plurality of sources, wherein one source of said plurality of sources is fetal cord blood, fetal tissue, a placenta, a postpartum placenta, or postpartum placenta perfusate; the content of each of said units being known with respect to the identities and numbers at least some of the plurality of potent cells comprising said unit; each of said units being assayed to ensure the accuracy of said identities and numbers.

51-53. (cancelled)